SGLT2 HYPE project

SGLT2-HYPE: A New Approach to Hypertension Management Hypertension remains a major health challenge, affecting over 80 million people in the EU and contributing to one million deaths each year. While treatments exist, many patients struggle to keep their blood pressure under control, increasing their risk of heart and kidney diseases. Our Mission: The SGLT2-HYPE trial is a groundbreaking international study investigating dapagliflozin, a promising SGLT2 inhibitor commonly used for diabetes and heart failure. With nearly 3,200 elderly participants at cardiovascular risk, this seven-year study will provide crucial insights into how this treatment can improve blood pressure control and protect vital organs. Why It Matters: By exploring innovative solutions, we aim to advance hypertension treatment and improve the lives of millions. Acknowledgement: The project has received funding from the European Unions`Horizon Europe research and innovation programme under the Grant Agreement no. 101156555. Disclaimer: The information contained reflects the views of the authors and does not necessarily represent the official position of the European Union. Neither the European Union nor its institutions can be held responsible for any use that may be made of the information contained herein.